Recombinant Human Active MAPKAPK2 (46-end) Protein, CF

The approximate molecular weight is 68 kDa and the average purity is 90%.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Active MAPKAPK2 (46-end) Protein, CF Summary

• Details of Functionality: The specific activity of MAPKAPK2 is typically 233-315 nmol/min/mg using a synthetic peptide substrate (RRLNRQLSVA-amide) (see Activity Assay Protocol).
• Source: Spodoptera frugiperda, Sf 9 (baculovirus)-derived human MAPKAPK2 protein
• Accession #: NM_032960
• N-terminal Sequence:

  Using an N-terminal GST tag

• Protein/Peptide Type: Recombinant Proteins
• Gene: MAPKAPK2
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• SDS-PAGE: 68 kDa

Packaging, Storage & Formulations

• Storage: This product is stable at ≤ ‑70 °C for up to 1 year from the date of receipt. For optimal storage, aliquot into smaller quantities after centrifugation and store at recommended temperature. Avoid repeated freeze-thaw cycles.
• Buffer: Supplied in 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM Glutathione, 0.1 mM EDTA, 0.25 mM DTT, 0.1 mM PMSF, 25% glycerol.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by Colloidal Coomassie® Blue stain at 5 μg per lane.
• Assay Procedure:
  • Active Kinase - Active MAPKAPK2 (0.1 μg/μL) diluted with Kinase Dilution Buffer III and assayed as outlined in sample activity plot. Note: These are suggested working dilutions and it is recommended that the researcher perform a serial dilution of Active MAPKAPK2 for optimal results.
  • Kinase Assay Buffer I - 25 mM MOPS, pH 7.2, 12.5 mM beta -glycerolphosphate, 25 mM MgCl₂, 5 mM EGTA, 2 mM EDTA. Add 0.25 mM DTT to the Kinase Assay Buffer prior to use.
  • Kinase Dilution Buffer III - Kinase Assay Buffer I diluted at a 1:4 ratio (5X dilution) with 50 ng/μL BSA solution.
  • 10 mM ATP Stock Solution - Prepare the ATP Stock Solution by dissolving 55 mg of ATP in 10 mL of Kinase Assay Buffer I. Store 200 μL aliquots at -20 °C.
  • [³³P]-ATP Assay Cocktail - Prepare 250 μM [³³P]-ATP Assay Cocktail in a designated radioactive work area by adding the following components: 150 μL of 10 mM ATP Stock Solution, 100 μL of [³³P]-ATP (1 mCi/100 μL), and 5.75 mL of Kinase Assay Buffer I. Store 1 mL aliquots at -20 °C.
  • Substrate - HSP27tide synthetic peptide substrate (RRLNRQLSVA-amide) diluted in distilled water to a final concentration of 1 mg/mL.
  1. Thaw the [³³P]-ATP Assay Cocktail in a shielded container in a designated radioactive work area.
  2. Thaw the Active MAPKAPK2, Kinase Assay Buffer I, Substrate, and Kinase Dilution Buffer on ice.
  3. In a pre-cooled microfuge tube, add the following reaction components bringing the initial reaction volume up to 20 μL:
     a. Diluted Active MAPKAPK2: 10 μL
     b. Substrate (1 mg/mL Stock Solution): 5 μL
     c. Distilled water (2-8 °C): 5 μL
  4. Set up the blank control as outlined in step 3, excluding the addition of the substrate. Replace the substrate with an equal volume of distilled water.
  5. Initiate the reaction by the addition of 5 μL [³³P]-ATP Assay Cocktail, bringing the final volume up to 25 μL. Incubate the mixture in a water bath at 30 °C for 15 minutes.
  6. After the 15 minute incubation period, terminate the reaction by spotting 20 μL of the reaction mixture onto individual pre-cut strips of phosphocellulose P81 paper.
  7. Air dry the pre-cut P81 strip and sequentially wash in a 1% phosphoric acid solution (dilute 10 mL of phosphoric acid and make a 1 liter solution with distilled water) with constant gentle stirring. It is recommended that the strips be washed a total of 3 intervals for approximately 10 minutes each.
  8. Count the radioactivity on the P81 paper in the presence of scintillation fluid in a scintillation counter.
  9. Determine the corrected cpm by removing the blank control value (see step 4) for each sample and calculate the kinase specific activity as outlined below.
     
     
     Calculation of [³³P]-ATP Specific Activity (SA) (cpm/pmol)
     Specific Activity (SA) = cpm for 5 μL [³³P]-ATP/pmol of ATP (in 5 μL of a 250 μM ATP stock solution; i.e. 1250 pmol)
     
     Calculation of Kinase Specific Activity (SA) (pmol/minutes/μg or nmol/minutes/mg)
     Corrected cpm from reaction / [(SA of ³³P-ATP in cpm/pmol) x (Reaction time in minutes) x (Enzyme amount in μg or mg)] x [(Reaction volume) / (Spot Volume)]

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Active MAPKAPK2 (46-end) Protein, CF

• EC 2.7.11
• EC 2.7.11.1
• MAP kinase-activated protein kinase 2
• MAPK-activated protein kinase 2
• MAPKAP kinase 2
• MAPKAPK2
• MAPKAPK-2
• mitogen-activated protein kinase-activated protein kinase 2
• MK2
• Rps6kc1

Background

MAPKAPK2 (MAPKAP kinase 2) is a Ser/Thr protein kinase which is regulated via direct phosphorylation by p38 MAP kinase (1). In conjunction with p38 MAP kinase, MAPKAPK2 is known to be involved in many cellular processes including stress and inflammatory responses, nuclear export, gene expression regulation, and cell proliferation. Heat shock protein 27 (HSP27) has been shown to be one of the substrates of MAPKAPK2 in vivo.

1. Stokoe, D. et al. (1993) Biochem. J. 296:843.

Publications for MAPKAPK2 (3705-KS)(1)

Publication using 3705-KS

• Y Shimada, H Shimura, R Tanaka, K Yamashiro, M Koike, Y Uchiyama, T Urabe, N Hattori Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator PLoS ONE, 2018-05-24;13(5):e0198039. 2018-05-24 [PMID: 29795667] (Bioassay)

Bioinformatics

• Gene Symbol: MAPKAPK2
• Uniprot:
  • NM_032960(Human)